Comparing the efficacy and safety of venetoclax combined with hypomethylating agents versus intensive chemotherapy as induction therapy in newly diagnosed core binding factor acute myeloid leukemia patients

被引：0
|
作者：
Shen, Jingyi [1 ,2 ]
Shan, Meng [1 ,2 ]
Chu, Mengqian [1 ,2 ]
Cai, Yiming [1 ,2 ]
Rui, Jingwen [1 ,2 ]
Chen, Suning [1 ,2 ]
Wu, Depei [1 ,2 ]
Xu, Yang [1 ,2 ]
机构：
[1] Soochow Univ, Jiangsu Inst Hematol, Natl Clin Res Ctr Hematol Dis, Affiliated Hosp 1, Suzhou, Peoples R China
[2] Soochow Univ, Inst Blood & Marrow Transplantat, Collaborat Innovat Ctr Hematol, Suzhou, Peoples R China
来源：
BLOOD CANCER JOURNAL | 2025年 / 15卷 / 01期
基金：
中国国家自然科学基金;
关键词：
MUTATIONS; CBFB-MYH11; KIT; AML;
D O I：
10.1038/s41408-025-01227-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Hematologic Predictors of Outcomes in Patients Undergoing Intensive Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia
    Arain, Saad
    Shah, Eshana
    Yavuz, Betul Gok
    Stettner, Sarah
    Calip, Gregory Sampang
    Khan, Irum
    Patel, Pritesh
    Quigley, John G.
    BLOOD, 2020, 136
  • [42] Venetoclax Combined with Hypomethylating Agents in Acute Myeloid Leukemia Patients Serious Complications Admitted to a Special Hematological Intensive Care Unit
    Liang, Peiqi
    Wu, Depei
    Xie, Yan
    Liu, Ziyi
    Fu, Jianhong
    BLOOD, 2023, 142
  • [43] AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia
    Todisco, Elisabetta
    Papayannidis, Cristina
    Fracchiolla, Nicola
    Petracci, Elisabetta
    Zingaretti, Chiara
    Vetro, Calogero
    Martelli, Maria Paola
    Zappasodi, Patrizia
    Di Renzo, Nicola
    Gallo, Susanna
    Audisio, Ernesta
    Griguolo, Davide
    Cerchione, Claudio
    Selleri, Carmine
    Mattei, Daniele
    Bernardi, Massimo
    Fumagalli, Monica
    Rizzuto, Giuliana
    Facchini, Luca
    Basilico, Claudia Maria
    Manfra, Ilenia
    Borlenghi, Erika
    Cairoli, Roberto
    Salutari, Prassede
    Gottardi, Michele
    Molteni, Alfredo
    Martini, Vincenza
    Lunghi, Monia
    Fianchi, Luana
    Cilloni, Daniela
    Lanza, Francesco
    Abruzzese, Elisabetta
    Cascavilla, Nicola
    Rivellini, Flavia
    Ferrara, Felicetto
    Maurillo, Luca
    Nanni, Jacopo
    Romano, Alessandra
    Cardinali, Valeria
    Gigli, Federica
    Roncoroni, Elisa
    Federico, Vincenzo
    Marconi, Giovanni
    Volpi, Roberta
    Sciume, Mariarita
    Tarella, Corrado
    Rossi, Giuseppe
    Martinelli, Giovanni
    CANCER, 2023, 129 (07) : 992 - 1004
  • [44] Venetoclax Combined with Homoharringtonine,Cytarabine and Aclacinomycin (HAAV) As Induction Therapy in Newly Diagnosed Young Adult Acute Myeloid Leukemia
    Zhou, Zepin
    Zhao, Xingli
    Suo, Xiaohui
    Bai, Guanchen
    Shi, Zeyan
    Luo, Yunya
    Tan, Yaxian
    Lu, Xinxiao
    Yuan, Linyu
    Zhang, Congcong
    Li, Yinling
    Gao, Sifeng
    Zhang, Jilei
    Li, Heng
    Zhao, Weihua
    Peng, Hongling
    Guo, Pengxiang
    Mi, Yingchang
    Liu, Kaiqi
    BLOOD, 2023, 142
  • [45] Advancing the standard: venetoclax combined with intensive induction and consolidation therapy for acute myeloid leukemia
    Lachowiez, Curtis A.
    Atluri, Himachandana
    DiNardo, Courtney D.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
  • [46] Outcome with Intensive Chemotherapy Compared to Hypomethylating AgentBased Induction in Patients Aged 70 Years or Older with Newly Diagnosed Favorable Risk Acute Myeloid Leukemia
    Ball, Somedeb
    Jain, Akriti G.
    Aguirre, Luis E. E.
    Al Ali, Najla
    Bewersdorf, Jan Philipp
    Hayden, Alexander
    Siddon, Alexa J.
    Lykon, Jillian
    Madarang, Ellen
    Sallman, David A.
    Padron, Eric
    Sweet, Kendra
    Lancet, Jeffrey E.
    Watts, Justin M.
    Swoboda, David M.
    Pollyea, Daniel A.
    Zeidan, Amer M.
    Komrokji, Rami S.
    BLOOD, 2021, 138
  • [47] Efficacy and Safety of Low-Dose Venetoclax Combined with Voriconazole Inpatients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy
    Meng, Danchen
    Ruan, Min
    Liu, Xinyao
    Wu, Wei
    Zhuang, Junling
    Ge, Jian
    Huang, Zhenqi
    Long, Zhangbiao
    BLOOD, 2023, 142
  • [48] Intensive Induction Chemotherapy with or without Gemtuzumab Ozogamicin Among Patients with Core-Binding Factor Acute Myeloid Leukemia
    Rojek, Alexandra E.
    McCormick, Benjamin J.
    Cwykiel, Joanna
    Odetola, Oluwatobi
    Abaza, Yasmin
    Achar, Rohan
    Shallis, Rory M.
    Bradshaw, Danielle
    Standridge, Meaghan
    Kota, Vamsi K.
    Badar, Talha
    Patel, Anand Ashwin
    BLOOD, 2023, 142
  • [49] A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Conventional Induction Chemotherapy for Newly Diagnosed Fit Adults with Acute Myeloid Leukemia
    Fathi, Amir T.
    Fell, Geoffrey G.
    El-Jawahri, Areej
    Perl, Alexander E.
    Jonas, Brian A.
    Dias, Ajoy L.
    Mims, Alice S.
    Borate, Uma
    Ragon, Brittany Knick
    Grunwald, Michael R.
    Peters, Mary Linton B.
    Graubert, Timothy A.
    Amrein, Philip C.
    Hock, Hanno R.
    Brunner, Andrew M.
    Hobbs, Gabriela S.
    Narayan, Rupa
    Neuberg, Donna S.
    Aldoss, Ibrahim
    BLOOD, 2022, 140 : 3284 - 3286
  • [50] Survival and Prognosis Among 301 Patients with Newly-Diagnosed Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy
    Karrar, Omer
    Iftikhar, Moazah
    McCullough, Kristen
    Johnson, Isla
    Abdelmagid, Maymona
    Al-Kali, Aref
    Alkhateeb, Hassan
    Begna, Kebede
    Mangaonkar, Abhishek A.
    Saliba, Antoine
    Hefazi, Mehrdad
    Litzow, Mark R.
    Hogan, William J.
    Shah, Mithun V.
    Patnaik, Mrinal M.
    Pardanani, Animesh D.
    Badar, Talha
    Murthy, Hemant S.
    Foran, James M.
    Palmer, Jeanne
    Sproat, Lisa
    Khera, Nandita
    Yi, Cecilia Y. Arana
    Tefferi, Ayalew
    Gangat, Naseema
    BLOOD, 2023, 142
12345